
Rapid Micro Biosystems (NASDAQ:RPID) reported first-quarter 2026 revenue growth and reaffirmed its full-year outlook, citing momentum in system placements, consumables and recurring revenue, while management said gross margin improvement remains a central priority for the year.
President and Chief Executive Officer Rob Spignesi said the company generated total revenue of $8 million in the quarter, up 11% from the prior-year period. The company placed six Growth Direct Systems during the quarter, compared with three in the first quarter of 2025. As of March 31, Rapid Micro had 196 systems placed globally, including 160 fully validated systems.